The Efficacy and Safety of Bivalirudin and Heparin in Patients with Acute Coronary Syndrome: a Systematic Review and Meta-analysis

Overview

Journal Syst Rev

Publisher Biomed Central

Date 2025 Feb 10

PMID 39930484

Authors

You Zhai

Hongcai Shang

Yan Li

Nan Zhang

Jisi Zhang

Shangwen Wu

Affiliations

Soon will be listed here.

Abstract

Background: Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are at high risk of thrombosis. However, bleeding-related complications during antithrombotic therapy remain a major barrier to effective treatment and can often lead to adverse outcomes. This meta-analysis aimed to determine the efficacy and safety of bivalirudin and heparin in patients with ACS after PCI.

Methods: Randomized controlled trials (RCTs) on the efficacy and safety of bivalirudin versus heparin in patients with ACS after PCI were identified from the PubMed, Embase, Cochrane Library, CBM, CNKI, WanFang, and VIP database until August 2024. The outcomes included all-cause mortality, major adverse cardiovascular events (MACEs), incidence of recurrent myocardial infarction, stent thrombosis, short-term bleeding, revascularization, and retransfusion. Meta-analysis was performed using RevMan 5.3 and Stata 12.0 softwares. The included studies were assessed for risk of bias using the Cochrane risk-of-bias assessment tool.

Results: A total of 70,199 patients from 27 randomized controlled trials (RCTs) were analyzed in this review. There were no significant differences between the bivalirudin and heparin groups in terms of all-cause mortality, major adverse cardiovascular events (MACEs), recurrent myocardial infarction, stent thrombosis within 30 days, or subacute stent thrombosis. Specifically, the incidence of short-term bleeding (P = 0.001) and retransfusion (P = 0.001) was significantly lower in the bivalirudin group compared to the heparin group. Conversely, the incidence of acute stent thrombosis (P < 0.0001) and revascularization (P = 0.009) was significantly higher in the bivalirudin group.

Conclusions: Compared with heparin, bivalirudin has definite anticoagulant effect in patients with acute myocardial infarction after PCI, and the risk of bleeding and the incidence of retransfusion were lower in the bivalirudin group. This review helps doctors in PCI management choose bivalirudin or heparin more precisely based on patients' conditions for better treatment and fewer adverse events.

References

Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L . Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015; 8(3):414-423. DOI: 10.1016/j.jcin.2014.10.015. View

Collins R, Macmahon S, Flather M, Baigent C, Remvig L, Mortensen S . Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996; 313(7058):652-9. PMC: 2351968. DOI: 10.1136/bmj.313.7058.652. View

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

Anderson L, Oldridge N, Thompson D, Zwisler A, Rees K, Martin N . Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2016; 67(1):1-12. DOI: 10.1016/j.jacc.2015.10.044. View

Li Y, Liu S, Guo Z, Yi H, Li C, Chen L . Discovery of potential pharmacodynamic ingredients of Dang-Gui-Si-Ni decoction based on absorbed ingredients and molecular docking. J Ethnopharmacol. 2021; 275:114045. DOI: 10.1016/j.jep.2021.114045. View

Erlinge D, Koul S, Omerovic E, Frobert O, Linder R, Danielewicz M . Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2018; 8(6):492-501. DOI: 10.1177/2048872618805663. View

Hu Y, Yao W, Jin D, Zhang J, Wang L, Zhang R . Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study. Medicine (Baltimore). 2021; 100(10):e25003. PMC: 7969278. DOI: 10.1097/MD.0000000000025003. View

Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg N . Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding. Int J Angiol. 2014; 23(4):227-32. PMC: 4244240. DOI: 10.1055/s-0034-1372244. View

Mehran R, Lansky A, Witzenbichler B, Guagliumi G, Peruga J, Brodie B . Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009; 374(9696):1149-59. DOI: 10.1016/S0140-6736(09)61484-7. View

10.

Lima F, Gruberg L, Aslam U, Ramgadoo M, Clase K, Trevisan A . The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention. J Interv Cardiol. 2017; 31(2):177-184. PMC: 5897148. DOI: 10.1111/joic.12462. View

11.

Omerovic E, James S, Ramundal T, Frobert O, Linder R, Danielewicz M . Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years. Cardiovasc Revasc Med. 2024; 66:43-50. DOI: 10.1016/j.carrev.2024.03.025. View

12.

Moliterno D . A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus.... Catheter Cardiovasc Interv. 2011; 77(7):1001-9. DOI: 10.1002/ccd.22876. View

13.

Capranzano P, Angiolillo D . Tug of War Between Dual and Triple Antithrombotic Therapy in Atrial Fibrillation/PCI Patients With CKD. JACC Cardiovasc Interv. 2019; 12(16):1562-1565. DOI: 10.1016/j.jcin.2019.06.032. View

14.

Gurm H, Rajagopal V, Fathi R, Vivekanathan D, Yadav J, Bhatt D . Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005; 95(6):716-21. DOI: 10.1016/j.amjcard.2004.11.021. View

15.

Xiang D, Gu X, Song Y, Huang W, Tang L, Yin Y . Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. Chin Med J (Engl). 2013; 126(16):3064-8. View

16.

Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R . Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014; 384(9957):1849-1858. DOI: 10.1016/S0140-6736(14)60924-7. View

17.

Wang Q, Liu Y, Yang L, Zhou T, Zhang Q, Zhang Z . Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. BMC Cardiovasc Disord. 2024; 24(1):713. PMC: 11657573. DOI: 10.1186/s12872-024-04399-5. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Dong O, Friede K, Chanfreau-Coffinier C, Voora D . Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2022; 9(3):249-257. PMC: 10272926. DOI: 10.1093/ehjqcco/qcac031. View

20.

Cohen M, Sohal S . Editorial: Bivalirudin versus unfractionated heparin in acute myocardial infarction: Why are we still debating?. Cardiovasc Revasc Med. 2023; 61:62-63. DOI: 10.1016/j.carrev.2023.11.008. View